Abstract
765 Association Between Compliance and Clinical Recurrence in Patients With Quiescent Ulcerative Colitis Receiving MMX ® Mesalamine 2.4g/Day as Maintenance Therapy: Results of the Phase IV Simple Trial
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
